Download PDF
Thromb Haemost 1997; 78(01): 364-366
DOI: 10.1055/s-0038-1657553
Clinical trials of direct thrombin inhibitors
Schattauer GmbH Stuttgart

Clinical Trials of Direct Thrombin Inhibitors in Acute Ischaemic Syndromes

Harvey D White
Coronary Care and Cardiovascular Research, Green Lane Hospital, Auckland, New Zealand
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391
    CrossrefPubMedSearch in Google Scholar
  • 2 Granger CB, Hirsh J, Califf RM, Col J, White HD, Betriu A. et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I Trial. Circulation 1996; 93: 870-878
    CrossrefPubMedSearch in Google Scholar
  • 3 Antman EM. for the TIMI 9A Investigators Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-1630
    CrossrefPubMedSearch in Google Scholar
  • 4 Antman EM. Antiplatelet/antithrombotic agents. Presented at Plenary Seminar, Joint AHA/European Society of Cardiology Symposium: Contemporary Strategies for Acute Myocardial Infarction. American Heart Association, 68th Scientific Sessions, Anaheim, California, November 1995. Unpublished
    PubMed
  • 5 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-1637
    CrossrefPubMedSearch in Google Scholar
  • 6 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-782
    CrossrefPubMedSearch in Google Scholar
  • 7 Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988; 77: 1213-1220
    CrossrefPubMedSearch in Google Scholar
  • 8 Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657-665
    CrossrefPubMedSearch in Google Scholar
  • 9 Eisenberg PR, Miletich JP. Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood. Thromb Res 1989; 55: 635-643
    CrossrefPubMedSearch in Google Scholar
  • 10 Lee CD, Mann KG. Activation/inactivation of human coagulation factor V by plasmin. Blood 1989; 73: 185-190
    PubMedSearch in Google Scholar
  • 11 Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990; 81: 219-225
    CrossrefPubMedSearch in Google Scholar
  • 12 Kleiman NS, White HD, Ohman EM, Ross AM, Woodlief LH, Califf RM. et al. Mortality within 24 hours of thrombolysis for myocardial infarction: the importance of early reperfusion. Circulation 1994; 90: 2658-2665
    CrossrefPubMedSearch in Google Scholar
  • 13 Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A. et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. Circulation 1995; 91: 1923-1928
    CrossrefPubMedSearch in Google Scholar
  • 14 Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS. et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994; 23: 0993-1003
    CrossrefPubMedSearch in Google Scholar
  • 15 Zoldhelyi P, Janssens S, Lefevre G, Collen D, Van deWerf F. for the GUSTO 2 A Investigators Effects of heparin and hirudin (CGP39393) on thrombin generation during thrombolysis for acute myocardial infarction [abstract]. Circulation 1995; 92 (Suppl. 01) I000-I740
    PubMedSearch in Google Scholar
  • 16 Gold HK, Torres FW, Garabedian HD, Werner W, Jang I, Khan A. et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993; 21: 1039-1047
    CrossrefPubMedSearch in Google Scholar
  • 17 White HD, Aylward PE, Frey M, Adgey J, Nair R, Hillis WS. et al. A randomized, double-blind comparison of Hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Submitted for publication.
    PubMed